Related Experiment Video

Updated: Oct 25, 2025

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3
08:36

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3

Published on: April 7, 2023

1.3K

Tofacitinib: Real-World Data and Treatment Persistence in Rheumatoid Arthritis

Ilaria Bertoldi1, Roberto Caporali2

  • 1Medical Department, Pfizer Italy, Rome, Italy.

Open Access Rheumatology : Research and Reviews
|August 5, 2021
PubMed

Insights

Tofacitinib effectively treats rheumatoid arthritis (RA) in real-world settings, showing comparable persistence to biologic therapies and a safety profile consistent with clinical trials.

Area of Science:

  • Rheumatology
  • Pharmacology
  • Immunology

Background:

  • Tofacitinib is an oral Janus kinase (JAK) inhibitor for rheumatoid arthritis (RA).
  • Extensive clinical trial data support its efficacy and safety in RA.
  • Real-world evidence is crucial for understanding long-term outcomes.

Purpose of the Study:

  • To review recent real-world evidence on tofacitinib's effectiveness in RA.
  • To evaluate treatment persistence and safety/tolerability in routine clinical practice.
  • To compare real-world findings with existing clinical trial data.

Main Methods:

  • Literature review of studies published from April 2018 to October 2020.
  • Focus on retrospective, prospective, and observational real-world studies.
  • Analysis of effectiveness, treatment persistence, and safety/tolerability data.

Main Results:

  • Real-world studies confirm tofacitinib's effectiveness in RA patients.
  • Treatment persistence was comparable to biologic disease-modifying anti-rheumatic drugs (bDMARDs).
  • Safety findings align with the established profile for tofacitinib 5 mg twice daily.

Conclusions:

  • Real-world data support the efficacy of tofacitinib in RA management.
  • Tofacitinib demonstrates favorable treatment persistence and a consistent safety profile.
  • Findings reinforce the value of tofacitinib in diverse RA patient populations.
Keywords:
effectivenesspersistencereal-worldrheumatoid arthritis

More Related Videos

An Adoptive Transfer Model of Rheumatoid Arthritis in Mice07:37

An Adoptive Transfer Model of Rheumatoid Arthritis in Mice

Published on: June 6, 2025

542
Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain04:50

Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain

Published on: May 16, 2025

464

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
264
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
290
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
251
Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
279
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.5K
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
9.7K